Akynzeo 300-0.5 MG capsules
Ended Awarded Last action
- Contract number
- SPE2DR26FQU9A
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,087
Award facts
- Contract value 100% obligated
- $28,087.03 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $28,087.03 to AmerisourceBergen Drug Corp for the supply of AKYNZEO 300-0.5 mg capsules. This firm fixed-price contract was competitively awarded without set-aside restrictions and is scheduled for completion by January 21, 2026. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania. The company serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The delivery order will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AKYNZEO, a brand-name antiemetic medication commonly used in oncology care to prevent chemotherapy-induced nausea and vomiting, represents one of many specialized pharmaceutical products delivered through AmerisourceBergen's extensive federal contract portfolio with DLA and related military healthcare agencies.
Quick answers
Who was awarded contract SPE2DR26FQU9A?
SPE2DR26FQU9A was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FQU9A worth?
The government has obligated $28,087 on SPE2DR26FQU9A.
Is contract SPE2DR26FQU9A an order under another contract?
Yes. SPE2DR26FQU9A is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQU9A competed?
The extent of competition for SPE2DR26FQU9A was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award